Life Science News

Sessions will include DTM™ SCS endurance therapy 3-month outcomes for patients with chronic back and leg pain Medtronic plc a global leader in healthcare technology, today announced its schedule for presentations at the 25th Annual North American Neuromodulation Society meeting, taking place January 13-15, 2022 in Orlando, Florida . Medtronic therapies and technologies will be represented as part of 23 podium and ...

Sessions will include DTM™ SCS endurance therapy 3-month outcomes for patients with chronic back and leg pain

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced its schedule for presentations at the 25th Annual North American Neuromodulation Society meeting, taking place January 13-15, 2022 in Orlando, Florida . Medtronic therapies and technologies will be represented as part of 23 podium and poster presentations. The company will also welcome guests to booth #404 featuring an innovation suite and opportunities to learn from Medtronic scientists and engineers about the new Vanta™ recharge-free neurostimulator, as well as a new modified energy variation of Differential Target Multiplexed™ (DTM) Spinal Cord Stimulation known as DTM™ SCS endurance therapy. Medtronic will also showcase its targeted drug delivery options for patients with chronic pain.

Scientific Presentations
The following poster and oral scientific data presentations reflect evidence from Medtronic-sponsored research and collaborations with external partners. Poster presentations will be available to all attendees with an option to query the presenters throughout the conference.

DTM™ SCS and DTM™ SCS Endurance Therapy

  • "A Prospective Multi-Center Study of a Differential Target Multiplexed™ Stimulation Derivative in Therapy-Naïve Patients: Primary Endpoint and 3-Month Outcomes" – oral presentation by Dr. Kas Amirdelfan, M.D. on Friday, January 14 .
  • "Modeling Energy Demands of a Reduced-Energy Derivative of Differential Target Multiplexed™ Stimulation on a Rechargeable and Recharge-free Systems" – poster presentation by Dr. David Provenzano , M.D. on Friday, January 14 .
  • "A RCT Comparing Traditional and DTM SCS for Chronic Back and Lega Pain : Profound Pain Relief, Functional and QoL Benefits" – oral presentation by Dr. Harold Cordner , M.D. on Saturday, January 15 .
  • "A Randomized Controlled Trial of DTM™ SCS Compared to Traditional SCS for Intractable Chronic Low Back and Leg Pain: Pain Relief, Therapy Satisfaction and Sensory Experience" – oral presentation by Dr. Michael Fishman , M.D. on Saturday, January 15 .
  • "Successful Reduction of Chronic Upper Limb and Neck Pain Using DTM SCS" – e-poster presentation by Dr. Ricardo Vallejo , M.D.

DTM™ SCS Pre-Clinical Presentations

  • "Transcriptomics of Differential Target Multiplexed SCS Using Reduced Energy in a Model of Neuropathic Pain" – oral presentation by David Cedeno , Ph.D. on Saturday, January 15 .
  • "Cell-Specific Transcriptomics of DTM SCS in a Model of Neuropathic Pain: Effect of Stimulation Intensity" oral presentation by Dr. Ricardo Vallejo , M.D. on Saturday, January 15 .
  • "SCS Alters Spinal Cord Gene Expression" – oral presentation by David Cedeno , Ph.D. on Saturday, January 15 .
  • "Differential Target Multiplexed SCS Modulated MAPK Pathway in an Animal Model of Neuropathic Pain" – oral presentation by Dana Tilley , Ph.D on Saturday, January 15 .
  • "Differential Target Multiplexed SCS Modulates mTOR Signaling in an Animal Model of Neuropathic Pain" – poster presentation by Dr. Francesco Vetri , M.D. on Friday, January 14 .

Targeted Drug Delivery

  • "Embrace TDD Primary Objective Results: Clinical Success Rate with Low Dose Intrathecal Morphine Monotherapy (LDITM)" – poster presentation by Dr. Chris Beuer , M.D. on Friday, January 14 .
  • "Low Dose Intrathecal Morphine Monotherapy (LDITM) for Chronic Nonmalignant Pain (NMP): Trialing Methods and Safety" – poster presentation by Dr. Michael Danko , M.D. on Friday, January 14 .
  • "Systemic Opioid Weaning and Low Dose Intrathecal Morphine Monotherapy (LDITM) for Chronic Nonmalignant Pain (NMP)" – poster presentation by Dr. Michael Danko , M.D. on Friday, January 14 .
  • "Patient Controlled Intrathecal Analgesia with Intrathecal Morphine for Chronic Nonmalignant Pain (NMP)" – poster presentation by Dr. Michael Saulino , M.D. on Friday, January 14 .
  • "Updated Longitudinal Data from the TDD Product Surveillance Registry: Effect of Pump Durable Design Changes" – poster presentation by Dr. Alaa Abd-Elsayed , M.D. on Friday, January 14 .
  • "Longitudinal Data from the Targeted Drug Delivery (TDD) Product Surveillance Registry (PSR): Trialing Characterization – e-poster presentation by Dr. Sam Eldabe, M.D.
  • "PSR TDD Latin America Experience" – poster presentation by Dr. Fabian Piedimonte , M.D.

Evoked Compound Action Potentials (ECAPs)

  • "Optimal Methods for Spinal Evoked Compound Action Potential Estimation" – oral presentation by Dr. Krishnan Chakravarthy , M.D., Ph.D. on Friday, January 14 .
  • "The Spinal Evoked Compound Action Potential as a Predictor for Perception" – oral presentation by Julie Pilitsis , M.D., Ph.D. on Friday, January 14 .
  • "The Effect of Electrode Selection on Optimal Spinal Evoked Compound Action Potential Sensing" – oral presentation by Dr. Michael Fishman , M.D. on Friday, January 14 .
  • "Clinical Feasibility of in Home, Closed-Loop Spinal Cord Stimulation with Differential Target Multiplexed Therapy" – oral presentation by Dr. Tristan Weaver , M.D. on Friday, January 14 .
  • "A Closed-Form Expression for the Spinal Evoked Compound Action Potential Growth Curve" – poster presentation by Leo Litvak , Ph.D.

Deep Brain Stimulation (DBS)

  • "Around-the-clock Monitoring of STN Beta-band LFPs Reveal Diurnal Variation in STN-DBS Parkinsonian Patients" –poster presentation by Dr. Genko Oyama , M.D. on Friday, January 14 .

Medtronic Sponsored Event
The following lunch symposium is open to attending healthcare professionals and will feature detailed clinical evidence and discussions with Medtronic and independent speakers.

  • "Personalizing Patient Care: How innovative therapies and technology are transforming SCS" presented by Dr. Erika Petersen , Dr. Krishnan Chakravarthy , Dr. Tammy Dann , and Jeff Kramer on January 14 at 12:00 p.m. :
    • Learn how DTM™ SCS therapy is uniquely inspired by science and proven in an RCT to provide superior pain relief on Intellis™
    • Hear how personalize care is advancing with the unveiling of the latest research results for DTM™ SCS endurance therapy
    • Discover how SCS will be transformed by future technologies

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn .

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.


Contacts:

Jeff Trauring

Ryan Weispfenning

Public Relations

Investor Relations

+1-763-760-0001

+1-763-505-4626

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/medtronic-announces-schedule-for-presentations-at-the-2022-north-american-neuromodulation-society-meeting-301459059.html

SOURCE Medtronic plc

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/January2022/12/c9841.html

News Provided by Canada Newswire via QuoteMedia

MDT
Cloud DX's Post-Surgical Monitoring Wearable Validated in Peer-Reviewed Study

Cloud DX's Post-Surgical Monitoring Wearable Validated in Peer-Reviewed Study

Cloud DX's Post-Surgical Monitoring Wearable Validated in Peer-reviewed Study For the ~800,000 1 Canadian surgery patients per year, continuous monitoring with Vitaliti™ could enable earlier intervention in cases of patient decline.

  • Validation of Cloud DX's Vitaliti™ continuous monitoring device clears way for regulatory approval starting in 2022.
  • Accurate continuous data collection supports earlier detection of changes in patient condition, enabling rapid interventions to improve patient outcomes.
  • Clear opportunity to impact up to ~800,000 1 surgical patients per year in Canada, deliverable through recent partnership with medical technology leader Medtronic.

Cloud DX (TSXV:CDX)(OTCQB:CDXFF), Leading Virtual Care Platform Cloud DX has announced publication of an independent peer-reviewed validation study of its unique Vitaliti™ product, a non-invasive wearable devices that provides continuous vital sign monitoring (CVSM) device. The study assessed regulatory compliance and post-surgery use in monitoring patients' vital signs in real-world conditions. The study found Vitaliti™ to be fully ISO 81060-2:2018 compliant for the continuous vital measurement, clearing the way for regulatory approval starting in 2022. The study also found that patients welcomed the comfortable, easy to use device. Instead of care teams taking vitals periodically after surgery, Cloud DX's Vitaliti™ was used for continuous monitoring, which could transform post-surgical care by enabling early detection if any deterioration occurs in patient health. On launch, Vitaliti™ will become a key component of Cloud DX's Connected Health™ ecosystem of remote monitoring technologies. Through Cloud DX's recent partnership with Medtronic Canada ULC (a subsidiary of Medtronic plc (MDT), a global leader in healthcare technology), wide deployment of Vitaliti™ is intended to initially improve post-operative care for surgical patients in Canada (up to 800,000 annually) and eventually in the United States (up to several million annually

Keep reading... Show less
InvestmentPitch Media Video Discusses Cloud DX's Selection by Medtronic for Canada-Wide Remote Patient Monitoring - Video Available on Investmentpitch.com

InvestmentPitch Media Video Discusses Cloud DX's Selection by Medtronic for Canada-Wide Remote Patient Monitoring - Video Available on Investmentpitch.com

Cloud DX Inc. (TSXV: CDX) (OTCQB: CDXFF) has been selected by Medtronic Canada ULC, to provide world-class virtual healthcare to Medtronic's patients across Canada. Medtronic Canada, (www.medtronic.ca) headquartered in Brampton, Ontario, with regional offices in Montreal and Vancouver, is the largest medical technology company in Canada, and a subsidiary of Medtronic plc (NYSE: MDT), a multi billion-dollar, global leader in medical technology, offering medical devices and therapies to more than 72 million people across 150 countries.

For more information, please view the InvestmentPitch Media "video" which provides additional information about this news and the company, along with comments from Robert Kaul, CEO of Cloud DX, about the significance of this news. If this link is not enabled, please visit www.InvestmentPitch.com and enter "Cloud DX" in the search box.

Keep reading... Show less
Cloud DX selected by Medtronic for national collaboration

Cloud DX selected by Medtronic for national collaboration

Medtronic selected Cloud DX for virtual and remote patient monitoring (RPM) solutions in exclusive corporate agreement

Cloud DX (TSXV: CDX) (OTCQB: CDXFF) has been selected by Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT), a global leader in healthcare technology, to provide world-class virtual healthcare to patients across Canada . This partnership advances Medtronic's commitment to improving patient outcomes and lowering overall costs along the care continuum. Cloud DX's remote patient monitoring (RPM) technology and services are exclusive to Medtronic and its Canadian client base, which is spread across Canada. Medtronic Canada delivers care in a broad range of clinical areas, including spinal and cardiac surgeries, cardiology, critical care, diabetes, vascular and renal care. Most clinical areas are expected to improve patient outcomes and satisfaction with some aspect of virtual care in the future. Initially, Medtronic seeks to integrate the Connected Health TM platform and associated services within both perioperative and complex chronic disease pathways in Canada .

Keep reading... Show less
10am mdt

Copper Fox Provides Corporate Update

Copper Fox Metals Inc. (TSXV: CUU) (OTCQX: CPFXF) ("Copper Fox" or the "Company") is pleased to provide an update on activities in advance of the Company's Annual General Meeting to be held on September 16, 2021.

Annual General Meeting ("AGM")
The AGM of the Company is scheduled for 10am MDT September 16, 2021. The meeting will be virtual in nature and all shareholders are encouraged to attend. To attend the AGM, please use the following link: https://www.gowebcasting.com/11461

Keep reading... Show less

Medtronic Announces Commercial Launch of the IN.PACT Admiral Drug-Coated Balloon in Japan

Medtronic (NYSE:MDT) today announced full commercial launch of the IN.PACT Admiral Drug-Coated Balloon (DCB) in Japan. The news follows the completion of a post-market clinical trial, which enrolled 300 subjects.

As quoted in the press release:

Keep reading... Show less
Bloom logo

Bloom Health Partners Receives DTC Eligibility

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a global platform for operational health, is pleased to announce that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company ("DTC"), a subsidiary of the Depository Trust & Clearing Corp. that manages the electronic clearing and settlement of publicly-traded companies in the United States.

The Company's shares will continue to trade in the USA, under the ticker BLMHF on the OTCQB Market. DTC eligibility reduces costs and accelerates the settlement process for investors and brokers allowing the Company's common shares to be traded over a much wider selection of brokerage firms by coming into compliance with their requirements.

Keep reading... Show less

Dr. Yehia Hashad Will Join Bausch + Lomb Corporation as Executive Vice President of Research & Development and Chief Medical Officer

Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health") has announced that Dr. Yehia Hashad will join Bausch + Lomb Corporation ("Bausch + Lomb") as executive vice president of Research & Development (R&D) and chief medical officer (CMO) effective Jan. 31, 2022 .

Dr. Hashad will join Bausch + Lomb from Allergan/AbbVie, where for the past 11 years he held various roles, including leading Allergan's global clinical development program for its eye care portfolio. Prior to that, he was with Novartis Pharma AG for five years, where he focused on ophthalmology, and also with T3A Pharma Group for nearly 10 years.

Keep reading... Show less
patient holding a visit with their doctor through a computer

Partnerships Key for MedTech in Today's Pandemic World

A recent new partnership in the health technology space has its origins in the COVID-19 pandemic, responding to important patient needs highlighted by the outbreak

Just before the end of last year, Medtronic Canada, a subsidiary of Medtronic (NYSE:MDT), announced plans to expand its outreach to patients via virtual solutions due to the limitations of a world still in a global pandemic.

Medtronic Canada is achieving these “virtual and remote patient monitoring solutions” via a business agreement with Cloud DX (TSXV:CDX,OTCQB:CDXFF), a health technology company. The deal is exclusive to Canada.

Keep reading... Show less
Bloom logo

Bloom Health Partners Announces Contract With State of Texas For K-12 Schools

Bloom launches program for K-12 schools for lab-based testing along with supply and management of rapid tests

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a global platform for operational health, announces that it has been awarded a state-wide contract for testing in Texas for K-12 schools for the remainder of the 2022 school year. Bloom's program includes both rapid and lab testing to make up a complete program that covers the needs of schools as they navigate the pandemic. RT-PCR testing will be conducted in Bloom's Dallas based laboratory. Rapid tests are being supplied by Bloom to schools, with results being managed on Bloom's cloud data platform.

Keep reading... Show less

Bausch Health Announces It Is Seeking To Refinance Its Existing Credit Agreement And Conditional Redemption Of Existing Notes - These Steps Will Enable Bausch + Lomb IPO And Facilitate Full Separation

- Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health" or the "Company") announced today that it is seeking to refinance its existing credit agreement (the "Credit Agreement" and such refinancing, the "Credit Agreement Refinancing"). The refinanced Credit Agreement is expected to consist of approximately $2.5 billion of term B loans (the "New Term B Loans") and a $975 million revolving credit facility. The Credit Agreement Refinancing is expected to occur only upon completion of the initial public offering (IPO) of Bausch + Lomb Corporation ("Bausch + Lomb" and such offering, the "Bausch + Lomb IPO") and a related debt financing by Bausch + Lomb (the "Bausch + Lomb Debt Financing"). At the time of the Bausch + Lomb IPO, Bausch + Lomb will initially remain a "restricted" subsidiary subject to the terms of the Credit Agreement covenants, but the Credit Agreement Refinancing is expected to permit Bausch Health to designate Bausch + Lomb as an "unrestricted" subsidiary outside the terms of the Credit Agreement covenants upon achievement of a 7.6x pro forma "Total Leverage Ratio." The Credit Agreement Refinancing is designed to facilitate the separation and distribution of Bausch + Lomb.

The Company also intends, subject to market conditions, to issue approximately $1.0 billion of secured debt securities (the "New Debt Securities"). The proceeds of the New Term B Loans and the offering of the New Debt Securities, along with proceeds from the Bausch + Lomb IPO and from the repayment of an intercompany note owed by Bausch + Lomb (which is expected to be funded by the Bausch + Lomb Debt Financing), are expected to be used to fund the redemption in full of our outstanding 6.125% Senior Notes due 2025 (the "6.125% Notes due 2025"), refinance all of the existing Term B Loans, fund a partial redemption of our outstanding 9.000% Senior Notes due 2025 (the "9.000% Notes due 2025" and, collectively with the 9.000% Notes due 2025, the "Existing Notes") and to pay related fees, premiums and expenses.

Keep reading... Show less

Medtronic announces results showing meaningful pain relief using DTM Spinal Cord Stimulation endurance therapy

DTM™ SCS endurance therapy enables long-lasting recharge-free performance on Vanta™ and 5-minute recharge on Intellis™ neurostimulators

- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced three-month results from an on-label, prospective, multi-center study 1 showing meaningful pain relief using DTM™ SCS endurance therapy, a modified, lower-energy variation of the company's Differential Target Multiplexed™ (DTM) Spinal Cord Stimulation (SCS) therapy for chronic overall, back or leg pain. At 3 months, patients treated with DTM SCS endurance therapy reported meaningful pain relief as measured by a 3.9 cm reduction in overall pain on the 10 cm Visual Analog Scale (VAS) 2 . Patients also reported an average 4.3 cm decrease in back pain, and an average 5.0 cm decrease in leg pain.

Keep reading... Show less

Latest Press Releases

Related News

×